Press Release

Vital Therapies – $40 Million Follow-on Offering

March 29, 2017

San Diego – March 29, 2017 – Cooley advised the underwriters in Vital Therapies’ $40.3 million follow-on offering of 10,062,500 shares of common stock, which includes the full exercise of the underwriters’ option to purchase an additional 1,312,500 shares.

Raymond James & Associates acted as book-running manager for the offering and National Securities Corporation acted as co-manager.

Vital Therapies, which is based in San Diego and trades on The NASDAQ Global Select Market as “VTL,” is a biotherapeutic company focused on developing a cell-based therapy targeting the treatment of acute forms of liver failure.

Cooley also advised the underwriters on Vital Therapies’ IPO in April 2014.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.